Skip to content

Shaun Hurley

4 papers in the library · 42 citations · publishing 2020-2025

Papers

Sort Most recent Most cited

Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.

British Journal of Pharmacology June 22, 2025 Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley et al. 9 citations

Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5-HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5-HT2A receptor ligand bias or signalling efficacy. Here, we investigated 5-HT2A receptor signalling properties of...

Increased 5-HT 2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics

bioRxiv (Cold Spring Harbor Laboratory) June 16, 2024 Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley et al. 1 citation preprint

ABSTRACT Background and Purpose Serotonergic psychedelic drugs are under renewed investigation for the potential treatment of several psychiatric disorders. While all serotonergic psychedelics have 5-HT 2A receptor activity, the explanation for why some 5-HT 2A receptor agonists are not psychedelic is unknown. To address this question, we investigated the 5-HT 2A receptor signalling bias and...

Rapid-acting antidepressant drugs modulate affective bias in rats

Science Translational Medicine January 10, 2024 Katie Kamenish, Roberto Arban, Aslihan Selimbeyoglu et al. 26 citations

How rapid-acting antidepressants (RAADs), such as ketamine, induce immediate and sustained improvements in mood in patients with major depressive disorder (MDD) is poorly understood. A core feature of MDD is the prevalence of cognitive processing biases associated with negative affective states, and the alleviation of negative affective biases may be an index of response to drug treatment....

Psilocybin rescues sociability deficits in an animal model of autism

bioRxiv (Cold Spring Harbor Laboratory) September 10, 2020 Irene Mollinedo-Gajate, Chenchen Song, Marcos Sintes-Rodriguez et al. 6 citations preprint

Abstract Autism spectrum disorder (ASD) is characterized by core deficits in social interaction. The classic serotonergic psychedelic psilocybin has been suggested as a therapeutic agent that may ameliorate in the core symptomology of ASD. We found that the acute response to psilocybin was attenuated in the prenatal valproic acid exposure mouse model of ASD, and importantly, psilocybin rescued...